Artificial Intelligence and Technology Collaboratory (P30 Clinical Trial Optional)
(RFA-AG-26-006)
National Institute on Aging
This Notice of Funding Opportunity (NOFO) invites Center Core (P30) applications for the National Institute on Aging's (NIA) Artificial Intelligence and Technology Collaboratories (AITC) program. The AITC program promotes the development and implementation of artificial intelligence (AI) approaches and technology through research projects for aging and Alzheimer's Disease (AD) and AD-related dementias (ADRD) research. All applications should propose strategies for addressing challenges surrounding AI and technology development and implementation, and to employ, when possible, best practices established in the fields of aging and AD/ADRD.
Claude D. Pepper Older Americans Independence Centers (P30 Clinical Trial Optional)
(RFA-AG-26-025)
National Institute on Aging
This Notice of Funding Opportunity (NOFO) invites applications for the Claude D. Pepper Older Americans Independence Centers (OAICs) award. The goal of the OAIC program is to establish centers of excellence in geriatrics research and research education to increase scientific knowledge leading to better ways to maintain or restore independence in older persons. OAIC awards are designed to develop or strengthen programs that focus on, and sustain progress in, a key area of aging research related to the mission of the OAIC program
Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
(PAR-25-446)
National Institute on Drug Abuse
The purpose of this notice of funding opportunity (NOFO) is to seek grant applications to support research on the discovery and development of interventions to prevent and/or treat substance use disorders (SUDs) and overdose, including interventions to treat co-morbid SUDs. This includes preclinical and clinical research studies that will have high impact and quickly yield the necessary results to advance candidate interventions closer to regulatory approval or clinical adoption. This NOFO will utilize the UG3/UH3 activity code.
Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)
(PAR-25-322)
Office of the Director, NIH
National Center for Complementary and Integrative Health
National Cancer Institute
National Eye Institute
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Institute on Aging
National Institute on Alcohol Abuse and Alcoholism
National Institute of Allergy and Infectious Diseases
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Institute of Biomedical Imaging and Bioengineering
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute of Environmental Health Sciences
National Institute of Mental Health
National Institute on Minority Health and Health Disparities
National Institute of Nursing Research
National Library of Medicine
Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
Office of Research on Women's Health
The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this notice of funding opportunity (NOFO) must not include preliminary data. Applications must include a separate attachment describing the change in research direction. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.
Aging Mammalian Tissues In Vitro (R21 Clinical Trial Not Allowed)
(RFA-AG-26-014)
National Institute on Aging
This notice of funding opportunity (NOFO) invites applications that propose interdisciplinary research that aims to develop complex mammalian 3-dimensional (3D) in vitro microphysiological systems (MPS) to model aging and recapitulate aging processes/phenotypes observed in the whole organism in vivo. This NOFO is primarily focused on human cell-derived MPS (e.g., tissue chip, organ-on-chip, tissue organoids). However, systems developed using cells of nonhuman mammalian origin are acceptable for benchmarking, system validation, or when their relevance to understanding human aging biology is justified. Supported projects will be expected to advance the adoption of MPS in aging biology research and as new human-relevant tools for drug discovery.
Partnerships for Development of Vaccines to Prevent Mycobacterium tuberculosis Infection and/or Disease (R01 Clinical Trial Not Allowed)
(RFA-AI-25-022)
National Institute of Allergy and Infectious Diseases
The purpose of this notice of funding opportunity (NOFO) is to solicit research applications focused on preclinical development of lead candidate vaccines to prevent Mycobacterium tuberculosis (Mtb) infection and/or disease, and to increase the clinical pipeline of viable vaccine candidates.
Tobacco Regulatory Science Small Grant Program for New Investigators (R03 Clinical Trial Optional)
(RFA-OD-25-008)
National Institutes of Health
National Cancer Institute
National Heart, Lung, and Blood Institute
National Institute on Drug Abuse
This Notice of Funding Opportunity (NOFO) aims to support new biomedical, behavioral, and social science investigators who are in the early stages of establishing independent careers in tobacco regulatory research. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies, secondary analysis of existing data, small, self-contained research projects, development of research methodology, and development of new research technology. Applicants are encouraged to conduct projects that ultimately have the potential to inform regulations on tobacco product manufacturing, distribution, and marketing. Research projects must address one or more High-Priority Research Topic(s) related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31.
The awards under this NOFO will be administered by NIH using funds made available through FDA CTP and the FSPTCA. Research results from this NOFO are expected to generate findings and data directly relevant to informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.
Asthma and Allergic Diseases Cooperative Research Centers (U19 Clinical Trial Optional)
(RFA-AI-24-079)
National Institute of Allergy and Infectious Diseases
The purpose of this notice of funding opportunity (NOFO) is to invite applications from single institutions or consortia of institutions to participate in the Asthma and Allergic Diseases Cooperative Research Centers (AADCRC) program. The program will support centers that integrate clinical and translational research to conduct studies on the mechanisms underlying the onset and progression of diseases of interest, including asthma, rhinitis (allergic and non-allergic), chronic rhinosinusitis, atopic dermatitis, food allergy, and drug allergy. The overarching goal of the program is to improve the understanding of the pathogenesis of these conditions and to provide a rational foundation for new, effective treatments and prevention strategies.
